Yale University School of Medicine, Section of Medical Oncology, 333 Cedar Street, FMP 116, New Haven, CT 06520, USA.
Expert Opin Investig Drugs. 2010 Mar;19(3):357-69. doi: 10.1517/13543781003593962.
The overexpression of EGFR has been documented in 30-90% of cases of advanced colorectal cancer (CRC). An increased understanding of the EGFR pathway in CRC has paved the way for the development of other targeted agents to augment therapeutic efficacy as well as for efforts to circumvent tumor resistance to therapy.
Our aim is to discuss the recent progress in the role of the EGFR pathway, the status of anti-EGFR therapeutic agents currently in use and the rationale for the development of novel agents that work along the pathway for the treatment of CRC.
The readers will learn about the development and evolution of mAbs directed against EGFR as well as tyrosine kinase inhibitors in the management of CRC patients. In the same vein, determination of optimal dosing and better methods of defining those subsets of patients most likely to benefit will be discussed.
All these data must encourage clinicians and basic researches to continue in their efforts to untangle the network behind EGFR and try to focus all that effort towards improving patient's quality of life as well as survival.
表皮生长因子受体 (EGFR) 的过度表达已在 30-90%的晚期结直肠癌 (CRC) 病例中被记录。对 CRC 中 EGFR 通路的深入了解为开发其他靶向药物以提高治疗效果以及努力规避肿瘤对治疗的耐药性铺平了道路。
我们的目的是讨论 EGFR 通路的最新进展、目前正在使用的抗 EGFR 治疗药物的现状以及沿着该通路开发新型药物治疗 CRC 的基本原理。
读者将了解针对 EGFR 的单克隆抗体和酪氨酸激酶抑制剂在 CRC 患者管理中的发展和演变。同样，将讨论确定最佳剂量和更好的方法来确定最有可能受益的患者亚组。
所有这些数据都必须鼓励临床医生和基础研究人员继续努力解开 EGFR 背后的网络，并努力将所有这些努力集中在提高患者的生活质量和生存上。
